MetLife Investment Management’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $249K | Buy |
73,298
+5,567
| +8% | +$18.9K | ﹤0.01% | 2071 |
|
|
2025
Q1 | $272K | Sell |
67,731
-6,667
| -9% | -$26.7K | ﹤0.01% | 2030 |
|
|
2024
Q4 | $483K | Buy |
74,398
+4,158
| +6% | +$27K | ﹤0.01% | 1822 |
|
|
2024
Q3 | $389K | Hold |
70,240
| – | – | ﹤0.01% | 1918 |
|
|
2024
Q2 | $392K | Buy |
70,240
+7,258
| +12% | +$40.5K | ﹤0.01% | 1857 |
|
|
2024
Q1 | $423K | Hold |
62,982
| – | – | ﹤0.01% | 1770 |
|
|
2023
Q4 | $574K | Hold |
62,982
| – | – | ﹤0.01% | 1608 |
|
|
2023
Q3 | $348K | Hold |
62,982
| – | – | ﹤0.01% | 1849 |
|
|
2023
Q2 | $538K | Buy |
62,982
+1,951
| +3% | +$16.7K | ﹤0.01% | 1652 |
|
|
2023
Q1 | $561K | Hold |
61,031
| – | – | ﹤0.01% | 1576 |
|
|
2022
Q4 | $623K | Hold |
61,031
| – | – | ﹤0.01% | 1497 |
|
|
2022
Q3 | $898K | Hold |
61,031
| – | – | 0.01% | 1245 |
|
|
2022
Q2 | $655K | Buy |
61,031
+6,277
| +11% | +$67.4K | 0.01% | 1481 |
|
|
2022
Q1 | $590K | Buy |
54,754
+48,305
| +749% | +$521K | ﹤0.01% | 1668 |
|
|
2021
Q4 | $105K | Hold |
6,449
| – | – | ﹤0.01% | 2388 |
|
|
2021
Q3 | $138K | Buy |
+6,449
| New | +$138K | ﹤0.01% | 2288 |
|